Teresa Helsten, MD
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling (NCT02846766) | Teresa Helsten, MD | 2018-07-01 |
| Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations (NCT02747797) | Teresa Helsten, MD | 2017-04-01 |
Track Teresa Helsten, MD automatically
Every clearance here is in the API, with alerts when new ones post.